← Eichor
Study identifier: NCT05934331 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Condition: Malignant Neoplasms of Digestive Organs  ·  Sponsor: LaNova Medicines Zhejiang Co., Ltd.

PhasePhase 2
Planned participants276
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.

This description comes directly from the study's public registry record.

Talk to the study team

Alex Yuan  ·  021-68889618  ·  AlexYuan@Lanovamed.com

Paul Kong  ·  021-68889618  ·  paulkong@lanovamed.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai East HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05934331